1	
2	Lack of evidence for infectious SARS-CoV-2 in feces and sewage
3	
4	Sandra Albert <sup>1</sup> , Alba Ruíz <sup>2</sup> , Javier Pemán <sup>2</sup> , Miguel Salavert <sup>2</sup> , Pilar Domingo-
5	Calap <sup>1,3*</sup>
6	
7	
8	
9	
10	<sup>1</sup> Instituto de Biología Integrativa de Sistemas, Universitat de València-CSIC,
11	Paterna, Spain
12	<sup>2</sup> Instituto de Investigación Sanitaria La Fe, Hospital Universitari i Politècnic La
13	Fe, Valencia, Spain
14	<sup>3</sup> Department of Genetics, Universitat de València, Burjassot, Spain
15	
16	
17	*corresponding author: Pilar Domingo-Calap, pilar.domingo@uv.es, +34 963
18	543 261, ORCID: 0000-0003-2829-8809
19	

#### 20 Abstract

Purpose: The SARS-CoV-2 coronavirus is a respiratory virus whose primary route of transmission is airborne. However, it has been shown that the virus can replicate in gastrointestinal cells, can be excreted in feces, and can reach sewage systems. Although viral RNA has been found in patient feces and sewage, little is known about the potential fecal-oral transmission of the coronavirus. Determining the presence of infective viral particles in feces and sewage is necessary to take adequate control measures and to discover new routes of coronavirus transmission.

Methods: Feces and urine of COVID-19 patients, and wastewater samples at the time
of high prevalence in the region under study (Valencia, Spain), have been analyzed
both by molecular methods and cell culture.

**Results**: Presence of SARS-CoV-2 in feces of COVID-19 patients has been detected, even in patients without gastrointestinal symptoms, suggesting that viral shedding though stool is common. In addition, we have developed a sample concentration methodology that allows us to maintain the infectivity of the viral particles present in the samples. Finally, inoculation of cell cultures with fecal and sewage concentrated samples do not evidence the presence of infective viral particles.

Conclusion: There is no evidence of the presence of infectious SARS-CoV-2 in feces
and sewage, suggesting that fecal-oral transmission is not a primary route. However,
larger-scale efforts are needed to elucidate whether the fecal-oral transmission should
be considered, especially with the emergence of new viral variants.

41

#### 42 Keywords

43 SARS-CoV-2; COVID-19, viral infectious particles; fecal-oral transmission

44

## 45 **Declarations**

## 46 Funding

- This research was funded by FONDO-COVID19 COV20/00210 funded by Instituto de Salud Carlos III to P.D-C. P.D-C. was supported by a Ramón y Cajal
- 49 contract from the Spanish Ministry of Science and Innovation, Call 2019.

## 50 **Conflicts of interest**

51 The authors have no conflicts of interest to declare.

## 52 Availability of data and material

- 53 The data that support the findings of this study are available from the
- 54 corresponding author, upon reasonable request.

## 55 Code availability

56 Not applicable.

## 57 Ethics approval

- 58 This study has been approved by the ethics committee of the Instituto de
- 59 Investigación Sanitaria La Fe (Valencia, Spain).

## 60 Consent to participate

61 Informed consent was obtained from all individual participants included in the 62 study.

## 63 **Consent for publication**

64 The authors declare consent for publication.

## 65 Introduction

66 Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has caused a 67 pandemic affecting the entire world. Although the main transmission route is via 68 droplets or aerosols [1], it has been shown that the virus can replicate in intestinal 69 mucosa [2], suggesting that viral excretion via feces could result in fecal-oral 70 transmission of SARS-CoV-2 [3, 4]. Despite the efforts to isolate viral infectious particles from feces, little is known about the possibility of infecting new hosts via feces. 71 72 In a first approach, it is necessary to determine the proportion of patients excreting 73 virus in stool by analyzing fecal samples and testing them by molecular methods to detect viral RNA. In a second step, positive samples should be used to inoculate target 74 75 cells expressing angiotensin-converting enzyme 2 (ACE2), the main receptor for 76 SARS-CoV-2 [5], to determine the presence of infectious viruses in stool. Viral shedding in stool has been suggested to be more prolonged than in the respiratory 77 78 tract, up to 5 weeks after respiratory samples have tested negative for SARS-CoV-2 79 RNA, even in mild or non-symptomatic patients [6, 7], including children [8].

80 The presence of SARS-CoV-2 RNA in feces has interesting applications, such 81 as the implementation of new detection techniques through anal swabs (Sun et al. 82 2020), or epidemiological surveillance of SARS-CoV-2 through wastewater [10]. 83 However, further efforts should be made to determine the proportion of patients 84 shedding virus through feces, viral load per individual, and other parameters in order to 85 use this specimen as a monitoring tool to correlate with incidence in the population. 86 Therefore, it is important to determine whether positive specimens contain infectious 87 particles, as only a few case reports have shown that viral infectious particles are found 88 in stool [11-13]. Recently, fecal-oral transmission has been proposed as the most 89 plausible explanation for two independent outbreaks in China, suggesting viral spread 90 vis sewage aerosols in a building [14], and via sewage in a residential home [15]. In 91 both cases, SARS-CoV-2 RNA sequencing supported the hypotheses. However,

92 further efforts should be done to assess the fecal-oral route in SARS-CoV-2, and 93 provide data based on the presence of infectious viral particles confirming the new 94 route of transmission [12].

Here we propose the first attempt to evaluate the fecal excretion of SARS-CoV-2 in Spain, and the presence of viral infectious particles in feces, in a single-center study based on a small cohort of COVID-19 patients. In addition, to determine the possibility of the fecal-oral route, SARS-CoV-2 positive wastewater samples from Wastewater Treatment Plants of Valencia (Spain) were used to study the presence of viral particles.

#### 101 Materials and Methods

#### 102 Human subjects

103 This study has been approved by the ethics committee of the Instituto de 104 Investigación Sanitaria La Fe (Valencia, Spain) to use patient samples, including urine 105 and feces. In total, eight mild-symptomatic patients admitted to the Hospital Universitari y Politècnic La Fe between June and December 2020 we enrolled in this study. 106 107 Informed consent was obtained from each patient. The criterion for inclusion in the 108 study was to be over 18 years of age. Diagnosis and data collection from medical 109 records were used. RT-qPCR on nasopharyngeal swabs was performed at the hospital 110 following internal guidelines using different commercial available kits (BioFire® 111 Respiratory Panel 2.1 (BioFire Defense LLC and BioFire Diagnostics LLC), Alinity m SARS-CoV-2 assay (Abbott Molecular), and Simplexa<sup>™</sup> COVID-19 Direct (DiaSorin 112 Molecular LLC)). Unfortunately, we were not able to recover the Ct values from 113 114 nasopharyngeal swabs. Stool and urine samples were both suspended in Sigma 115 Virocult viral transport medium without viral inactivators (W951S, MWE medical wire) 116 and kept at 4°C until laboratory handling within 24 hours.

117 Sewage samples

Wastewater from the metropolitan Wastewater Treatment Plants of Valencia (Spain) belonging to the Empresa Pública de Saneamiento de Aguas Residuales (EPSAR, Generalitat Valenciana) was sampled from December 2020 to January 2021. Grab and four-hour composite samples of 200 mL of sewage were collected in the morning. Samples were kept at 4 °C until they were processed in the laboratory within 24h of collection.

#### 124 Sewage sample concentration

125 Sewage samples were treated to allow viral particle concentration. Three were tested: flocculation, ultra-filtration, and high-speed 126 different methods centrifugation. As a first common step, 10<sup>5</sup> particle forming units (PFU) of the 127 128 transmissible gastroenteritis virus (TGEV) were added to the wastewater samples as a surrogate virus. This was followed by gentle centrifugation at  $3,000 \times q$ , 10 min, at 4°C, 129 130 and the supernatant was filtered through a 0.45 µm pore. Aluminum-driven flocculation 131 was done in 50 mL of sewage, adjusting to pH 6.0, and adding 1:100 v:v of 0.9 N AICI3 132 solution. Al(OH)3 precipitate was formed and after pH readjustment to 6.0, samples were gently agitated for 15 min at room temperature, and spun at 1,700 x g for 20 min. 133 134 Pellets were resuspended into 10 mL of 3% beef extract (pH 7.4), and shaken for 10 135 min at 150 rpm. Samples were then centrifuged at 1,900 x g for 30 min and the pellet 136 was resuspended in 1 mL of phosphate buffer (PBS) (Randazzo et al., 2020). Ultra-137 filtration method was done in 20 mL of sewage. Amicon tubes with 100KDa filters were 138 used, and after  $3,200 \times q$ , 30 min, at 4°C, the residual liquid in the upper part of the filter was collected. High-speed centrifugation method was done in 35 mL of filtered 139 140 wastewater, centrifuged at 80,000 x g, 3 h 30 min, at 4°C. The supernatant was removed and the pellet was resuspended in 500 µL of PBS. 141

#### 142 Processing of fecal samples

Fecal samples were resuspended in PBS to a final volume of 2 mL. Samples were then centrifuged at  $3220 \times g$ , 10 min, at 4°C twice to recover viruses in the supernatant. The supernatants were filtered through a 0.45 µm pore.

#### 146 RNA extraction and RT-qPCR

147 RNA extraction was performed with the Nucleospin RNA Virus Kit (Macherey-Nagel) following the recommended protocols. RT-qPCR was performed with the 148 149 GoTaq® Probe 1-Step RT-qPCR System (Promega) using the U.S. Center for Disease 150 Control N1 and N2 primers sets (2019-nCoV CDC EUA Kit, 1000rxn) provided by IDT (Integrated DNA Technologies). For each RT-qPCR run, calibration curves were 151 performed using the 2019-nCoV\_N\_Positive Control provided by IDT. In addition, 152 153 positive and negative controls (concentration, extraction and PCR) were included. To estimate viral loads, cycle threshold (Ct) values were used to calculate genomic copies 154 155 (gc) per liter in the original sample due to calibration curves. Ct values bellow 40 were 156 considered positive for SARS-CoV-2, as previously proposed [16]. All the experiments 157 were performed in duplicate. In addition, and as an internal control, in-house TGEV primers were used to evaluate the efficacy of the protocol. 158

#### 159

#### High-throughput sequencing

Genomic sequencing was performed following the protocol of retrotranscription and amplification of ARTIC, using the amplification protocol, using the V3 version scheme for multiplex PCRs. This was followed by the preparation of libraries using the Nexus kit using the Nextera Flex kit (Illumina) and their sequencing on the Illumina MiSeq platform (paired-end reads 2x200 bp) [17].

#### 165 Cell culture

Fecal specimens and sewage samples with highest RNA detected by RT-qPCR
 were used to inoculate Vero E6 cells. To maintain infectivity, the high-speed

168 centrifugation method was used to concentrate viruses in positive samples, as169 previously tested with TGEV.

Sewage samples were centrifuged at  $3000 \times g$ , 10 min, at 4°C and the supernatant was filtered through a 0.45 µm pore. Thirty-five mL of filtrate was centrifuged at 80,000 × g, 3h 30min, at 4°C and the pellet was resuspended in 500 µL of Dulbecco Modified Eagle Medium (DMEM) supplemented with 2% fetal bovine serum, non-essential amino acids, penicillin and streptomycin.

175 Fecal samples were centrifuged 3h 30min at 20,000 x g at 4°C to recover viruses, which were resuspended in 400 µL of Dulbecco Modified Eagle Medium 176 (DMEM) supplemented with 2% fetal bovine serum, non-essential amino acids, 177 178 penicillin and streptomycin, and 25 mM Hepes. All samples were analyzed undiluted 179 and at 1/10 dilution. Diluted samples were used to avoid potential sample inhibitors or 180 cytotoxic molecules. Negative controls were added in all experiments. For sewage, a 181 negative RT-qPCR sample sampled in July 2020 was used as a negative control. For 182 feces, a canine fecal sample was used as a negative control. Vero E6 cells were inoculated at 70% confluence with diluted and undiluted fecal or wastewater samples. 183 184 Cultures were incubated at 37°C and 5% CO<sub>2</sub> for six dpi. Replication of SARS-CoV-2 in cells cultures was analyzed by RT-qPCR, at 0 hpi, 48 hpi and 6 dpi. 100 µL of the 185 186 supernatant was recovered and treated with DNA/RNA Shield (Zymo Researh) for 187 each time point to inactivate the viruses and proceed to RNA extraction and RT-qPCR 188 as explained above. In addition, microscopy images were taken to detect cytopathic 189 effects of cell monolayers. All the experiments were performed in triplicate.

190 Results

191 Patients

192 This study was performed on a cohort of eight COVID-19 patients admitted to 193 the Hospital Universitari i Politècnic La Fe (Valencia, Spain) between June and

December 2020. In our cohort, 5 patients of the 8 showed respiratory symptoms, and only 3 had gastrointestinal (GI) symptoms. Other common symptoms, such as fever and headache, were very frequent in patients. None of the patients included in our cohort were admitted to intensive care units. Fecal and urine samples were collected from the patients to determine the presence of SARS-CoV-2, and in some of them we had access to longitudinal samples (Table 1).

#### 200 Sample concentration comparison

201 Different sample concentration methods were tested to select a protocol capable of concentrating the virus while maintaining viral infectivity, using the 202 203 transmissible gastroenteritis coronavirus (TGEV) as model. The three methods tested 204 were: ultrafiltration, aluminum-driven flocculation, and high-speed centrifugation. The 205 concentration factor was obtained by RTqPCR using in-house primers and probes, and 206 by plaque assay infecting swine testicular (ST) cells. Six replicates were performed per 207 method. For maintaining infectivity, high-speed centrifugation was the best method (concentration factor:  $31.29 \pm 6.49$ ), followed by ultrafiltration (concentration factor: 208 209 7.38 ± 1.26). In contrast, infectivity was impaired by aluminum-driven flocculation 210 (concentration factor:  $0.02 \pm 0.02$ ). As for RNA detection, high-speed centrifugation 211 obtained similar results to the aluminum-driven flocculation method (concentration 212 factor: 14.98 ± 0.91 vs. 16.42 ± 2.13), whereas ultrafiltration was not suitable 213 (concentration factor:  $2.85 \pm 0.87$ ). For these reasons, the high-speed centrifugation 214 method was chosen as the best in terms of concentration and maintenance of viral 215 infectivity.

## 216 Detection of SARS-CoV-2 RNA in fecal and urine samples

The presence of SARS-CoV-2 in the patient samples was evaluated by RTqPCR in urine and feces. Internal controls using the surrogate TGEV coronavirus were used in all the samples, validating the efficacy of our protocol (data not shown). The

220 results showed that 6 of the 8 patients had viral excretion in feces in at least one of the samples analyzed, ranging from  $8.34 \times 10^3$  gc/L to  $6.74 \times 10^6$  gc/L (Table 2). One of 221 222 the negative patients, it is worth mentioning that he was negative despite suffering from 223 GI symptoms. The absence of viral shedding in this patient was not expected, and a 224 possible explanation is that the sample was taken one month after the onset of the first 225 symptoms, suggesting that perhaps earlier sampling might have different results. In 226 parallel, urine samples were collected for patients to test for RNA detection. In our 227 dataset, one patient showed viral shedding in urine in two consecutive samples, despite the low viral load found (ranging from 5.60  $\times$  10<sup>4</sup> gc/L to 1.78  $\times$  10<sup>5</sup> gc/L). 228

#### 229 SARS-CoV-2 sequencing attempt in fecal samples

230 In addition, we wanted to sequence the RNA obtained in the feces to analyze 231 the variability found in stool. Unfortunately, the viral loads obtained in the feces of the 232 patients tested were too low for viral sequencing. Despite the low copy number per mL 233 in our samples, we attempted to sequence the sample with highest viral load, but the 234 results were insufficient for further analysis. Using the Illumina MiSeq sequencer, and 235 following the ARTICV3 + Nextera Flex protocol, only 13.28% of the SARS-CoV-2 236 genome was covered, with a coverage of 2 (unpublished data). Our results are 237 consistent with previous data in which samples with low viral load are difficult to 238 sequence [18]. Since the Ct values of the other samples were higher than those of the 239 tested sample, we decided not to continue with the sequencing protocol for the 240 remaining samples.

#### 241 Potential contribution of fecal shedding to SARS-CoV-2 transmission

To determine whether RNA found in feces was capable of infecting new hosts, we attempted to determine by cell culture the presence of infectious SARS-CoV-2 particles in positive samples, using 8 samples from 5 patients. Vero E6 cells were used as recommended cell models for SARS-CoV-2 infection [19]. Isolation of viral

particles from feces and inoculation of cell monolayers were performed. Three sampling points were analyzed, 0 hours post-infection (hpi), 48 hpi and 6 days postinfection (dpi). No cytopathic effect on Vero E6 cells was observed in any of the samples analyzed (Figure 1). However, supernatants were collected and RT-qPCR was performed to detect viral amplification. In all samples tested no SARS-CoV-2 RNA was detected, suggesting the absence of viral particles in the cultures tested, despite the RNA found in the fecal samples (Table 3).

## 253 Potential contribution of wastewater to SARS-CoV-2 transmission

254 Further, we wanted to determine the potential contribution of wastewater to 255 SARS-CoV-2 transmission. Eight sewage samples from wastewater treatment plants in 256 Valencia (Spain) between December 2020 and January 2021, where the incidence rate 257 in the target population was higher than 1000 per 100000 people. Samples were 258 concentrated by high-speed centrifugation to ensure virus viability and analyzed by RT-259 aPCR and cell culture. Again, despite the high viral load obtained in the samples (ranging from  $1.43 \times 10^4$  gc/L to  $1.48 \times 10^6$  gc/L) (Table 4), we were unable to detect 260 261 evidence of replication in our assays (Table 5).

## 262 Discussion

Fecal shedding of SARS-CoV-2 has been reported in patients with COVID-19 263 and in asymptomatic infected individuals. However, the possible fecal-oral transmission 264 265 route of the coronavirus is still under discussion. Our results are in agreement with 266 those previously published on the detection of SARS-CoV-2 in the stool of COVID-19 267 patients [20]. However, we were able to detect viral RNA in stool in 6/8 patients, being 268 a high percentage compared to previously published results, and suggesting that the 269 virus may be detected more frequently in stool than expected based on previously 270 published results [21]. Furthermore, our results suggest that GI symptoms and the 271 presence of SARS-CoV-2 in feces are not correlated, as only 3 patients had GI

medRxiv preprint doi: https://doi.org/10.1101/2021.05.11.21256886; this version posted May 11, 2021. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license.

272 symptoms. This result could have implications for the use of anal swabs as recently 273 suggested. However, the implementation of more sensitive detection methods 274 associated with fecal samples could be an interesting solution to develop non-invasive 275 easy-to-use, rapid tests, than can be performed by common users, avoiding 276 nasopharyngeal swabs, since nasal self-swabbing can lead to inadequate sample 277 collection resulting in false negative conclusions. Thus, the results obtained in this 278 study, despite the low number of patients included, suggest that the presence of 279 SARS-CoV-2 in feces is common, and support the use of anal testing for its detection.

280 To unravel the fecal-oral route of SARS-CoV-2 transmission, fecal samples 281 have been analyzed in cell culture for the presence of infectious viral particles. The lack 282 of evidence of infectivity in fecal samples could be due to the low viral load found in our 283 samples, with high Ct values, in contrast with previously published results in which 284 infectious coronavirus was found in a sample with a Ct value ranging 20-23 [11]. The 285 fact that only a few cases of infectious particles in feces have been reported so far 286 suggests that although transmission through feces might exists, it should not be 287 considered as a major route. To go further, sewage samples at the time of highest 288 incidence in Valencia (Spain) were tested in cell culture. Despite the high viral load 289 found in wastewater, no viral replication was detected in the samples tested, 290 suggesting that transmission of SARS-CoV-2 through stool or sewage should be minor 291 or absent. In agreement with our results, a recent study in China was unable to detect 292 viable virus in hospital wastewater [22].

We strongly suggest increased effort to continue testing more patients, including asymptomatic patients, to get a broader view of viral shedding in feces. Further evidence should be conducted in a single-center study involving a large cohort to draw supported conclusions. In addition, sewage sampled directly from sewers could be an interesting approach to detect possible infectious particles, avoiding the wastewater treatment plants, where viral particles could be inactivated due to external

factors such as temperature, humidity, or chemical agents in the matrix, which mayremove or impact the envelope.

we used RT-gPCR for RNA detection following the CDC 301 Finally, 302 recommendations, and the recommended cellular model for SARS-CoV-2 infection. 303 However, improved detection methodologies using more sensitive and efficient 304 techniques, both in molecular diagnostic and cell culture, could lead to different results. 305 Therefore, further characterization of fecal and sewage samples is mandatory to 306 unravel the possible fecal-oral route of SARS-CoV-2 transmission, and will be an 307 interesting topic for future research, especially with the emergence of new viral 308 variants.

#### 309 Acknowledgements

We thank to M. Carmen Montaner from the Hospital Universitari i Politècnic La Fe for her support in the collection of the samples. We thank the Generalitat Valenciana and the Empresa Pública de Saneamiento de Aguas Residuales (EPSAR) for providing access to wastewater. We also want thank Dr. Antonio Alcamí for the Vero E6 cells. This research was funded by FONDO-COVID19 COV20/00210 funded by Instituto de Salud Carlos III to P.D-C. P.D-C. was supported by a Ramón y Cajal contract from the Spanish Ministry of Science and Innovation, Call 2019.

317

#### 318 References

 Zhang R, Li Y, Zhang AL, Wang Y, Molina MJ (2020) Identifying airborne transmission as the dominant route for the spread of COVID-19. PNAS 117:14857–14863. https://doi.org/10.1073/pnas.2009637117

Xiao F, Tang M, Zheng X, Liu Y, Li X, Shan H (2020) Evidence for
 Gastrointestinal Infection of SARS-CoV-2. Gastroenterology 158:1831–1833.
 https://doi.org/10.1053/j.gastro.2020.02.055

Jones DL, Baluja MQ, Graham DW, Corbishley A, McDonald JE, Malham SK,
 Hillary LS, Connor TR, Gaze WH, Moura IB, Wilcox MH, Farkas K (2020)
 Shedding of SARS-CoV-2 in feces and urine and its potential role in person-to-

328 329		person transmission and the environment-based spread of COVID-19. Sci Total Environ 749:141364. https://doi.org/10.1016/j.scitotenv.2020.141364
330 331 332	4.	Guo M, Tao W, Flavell RA, Zhu S (2021) Potential intestinal infection and faecal- oral transmission of SARS-CoV-2. Nat Rev Gastroenterol Hepatol 18:269–238. https://doi.org/10.1038/s41575-021-00416-6
333 334 335	5.	Scialo F, Daniele A, Amato F, Pastore L, Matera MG, Cazzola M, Castaldo G, Bianco A (2020) ACE2: The Major Cell Entry Receptor for SARS-CoV-2. Lung 198:867–877. https://doi.org/10.1007/s00408-020-00408-4
336 337 338	6.	Mesoraca A, Margiotti K, Viola A, Cima A, Sparacino D, Giorlandino C (2020) Evaluation of SARS-CoV-2 viral RNA in fecal samples. Virol J 17:86. https://doi.org/10.1186/s12985-020-01359-1
339 340 341 342	7.	Wu Y, Guo C, Tang L, Hong Z, Zhou J, Dong X, Yin H, Xiao Q, Tang Y, Qu X, Kuang L, Fang X, Mishra N, Lu J, Shan H, Jiang G, Huang X (2020) Prolonged presence of SARS-CoV-2 viral RNA in faecal samples. Lancet Gastroenterol Hepatol 5:434–435. https://doi.org/10.1016/S2468-1253(20)30083-2
343 344 345 346	8.	Xu Y, Li X, Zhu B, Liang H, Fang C, Gong Y, Guo Q, Sun X, Zhao D, Shen J, Zhang H, Liu H, Xia H, Tang J, Zhang K, Gong S (2020) Characteristics of pediatric SARS-CoV-2 infection and potential evidence for persistent fecal viral shedding. Nat Med 26:502–505. https://doi.org/10.1038/s41591-020-0817-4
347 348 349 350	9.	Sun M, Guo D, Zhang J, Zhang J, Teng H-F, Xia J, Liu P, Ge Q-X, Wang M-Y Anal swab as the potentially optimal specimen for SARS-CoV-2 detection to evaluate the hospital discharge of COVID-19 patients. Future Microbiol 15:1101– 1107. https://doi.org/10.2217/fmb-2020-0090
351 352 353 354	10.	Hamouda M, Mustafa F, Maraqa M, Rizvi T, Aly Hassan A (2021) Wastewater surveillance for SARS-CoV-2: Lessons learnt from recent studies to define future applications. Sci Total Environ 759:143493. https://doi.org/10.1016/j.scitotenv.2020.143493
355 356 357	11.	Xiao F, Sun J, Xu Y, Li F, Huang X, Li H, Zhao J, Huang J, Zhao J (2020) Infectious SARS-CoV-2 in feces of patient with severe COVID-19. Emerg Infect Dis 26:1920-1922. https://doi.org/10.3201/eid2608.200681
358 359 360	12.	Cuicchi D, Lazzarotto T, Poggioli G (2020) Fecal-oral transmission of SARS-CoV- 2: review of laboratory-confirmed virus in gastrointestinal system. Int J Colorectal Dis 36:437–444. https://doi.org/10.1007/s00384-020-03785-7
361 362 363 364	13.	Jeong HW, Kim S-M, Kim H-S, Kim Y-I, Kim JH, Cho JY, Kim S, Kang H, Kim S-G, Park S-J, Kim E-H, Choi YK (2020) Viable SARS-CoV-2 in various specimens from COVID-19 patients. Clin Microbiol Infect 26:1520–1524. https://doi.org/10.1016/j.cmi.2020.07.020
365 366 367 368	14.	Kang M, Wei J, Yuan J, Guo J, Zhang Y, Hang J, Qu Y, Qian H, Zhuang Y, Chen X, Peng X, Shi T, Wang J, Wu J, Song T, He J, Li Y, Zhong N (2020) Probable Evidence of Fecal Aerosol Transmission of SARS-CoV-2 in a High-Rise Building. Ann Intern Med 173:974–980. https://doi.org/10.7326/M20-0928
369 370	15.	Yuan J, Chen Z, Gong C, Liu H, Li B, Li K, Chen X, Xu C, Jing Q, Liu G, Qin P, Liu Y, Zhong Y, Huang L, Zhu B-P, Yang Z (2020) Sewage as a Possible

Transmission Vehicle During a Coronavirus Disease 2019 Outbreak in a Densely
 populated Community: Guangzhou, China, April 2020. Clin Infect Dis ciaa1494 .
 https://doi.org/10.1093/cid/ciaa1494

- Wang W, Xu Y, Gao R, Lu R, Han K, Wu G, Tan W (2020) Detection of SARSCoV-2 in Different Types of Clinical Specimens. JAMA 323:1843–1844.
  https://doi.org/10.1001/jama.2020.3786
- 17. Quick J (2020) nCoV-2019 sequencing protocol.
- 378 https://doi.org/10.17504/protocols.io.bbmuik6w


Meredith LW, Hamilton WL, Warne B, Houldcroft CJ, Hosmillo M, Jahun AS,
 Curran MD, Parmar S, Caller LG, Caddy SL, Khokhar FA, Yakovleva A, Hall G,
 Feltwell T, Forrest S, Sridhar S, Weekes MP, Baker S, Brown N, Moore E, Popay
 A, Roddick I, Reacher M, Gouliouris T, Peacock SJ, Dougan G, Török ME,
 Goodfellow I (2020) Rapid implementation of SARS-CoV-2 sequencing to
 investigate cases of health-care associated COVID-19: a prospective genomic
 surveillance study. Lancet Infect Dis 20:1263–1271.

- 386 https://doi.org/10.1016/S1473-3099(20)30562-4
- Ogando NS, Dalebout TJ, Zevenhoven-Dobbe JC, Limpens RWAL, van der Meer
   Y, Caly L, Druce J, de Vries JJC, Kikkert M, Bárcena M, Sidorov I, Snijder EJ
   (2020) SARS-coronavirus-2 replication in Vero E6 cells: replication kinetics, rapid
   adaptation and cytopathology. J Gen Virol 101:925–940.
- 391 https://doi.org/10.1099/jgv.0.001453

Amirian ES (2020) Potential fecal transmission of SARS-CoV-2: Current evidence
 and implications for public health. Int J Infect Dis 95:363–370.
 https://doi.org/10.1016/j.ijid.2020.04.057

- 21. Cheung KS, Hung IFN, Chan PPY, Lung KC, Tso E, Liu R, Ng YY, Chu MY,
  Chung TWH, Tam AR, Yip CCY, Leung K-H, Fung AY-F, Zhang RR, Lin Y, Cheng
  HM, Zhang AJX, To KKW, Chan K-H, Yuen K-Y, Leung WK (2020)
  Gastrointestinal manifestations of SARS-CoV-2 infection and virus load in fecal
  samples from a Hong Kong cohort: systematic review and meta-analysis.
  Gastroenterol 159:81–95. https://doi.org/10.1053/j.gastro.2020.03.065
- Wang J, Feng H, Zhang S, Ni Z, Ni L, Chen Y, Zhuo L, Zhong Z, Qu T (2020)
  SARS-CoV-2 RNA detection of hospital isolation wards hygiene monitoring during
  the Coronavirus Disease 2019 outbreak in a Chinese hospital. Int J Infect Dis
  94:103–106. https://doi.org/10.1016/j.ijid.2020.04.024
- 405

## 407 Figure



408

409

410

Figure 1. Representative images of Vero E6 cultures obtained at different time points inoculated with fecal-treated samples. Undiluted and 1/10 diluted samples

413 were tested for each sample. Magnification: 40X. In patient 1, 1/7 and 2/7 refer to two

414 different samples.

## 415 Tables

416

## 417 Table 1. Main characteristics of the COVID-19 cohort included in the study. PCR

418 + nasopharyngeal swab to validate SARS-CoV-2 infection. GI: gastrointestinal.

419

Patie cod	Gender	Admission date	Fever	Headache	Odinophagy	Respiratory symptoms	Anosmia	Dysgeusia	GI symptoms
1	Male	Jun 2020	NO	YES	YES	NO	NO	NO	NO
2	Male	Jun 2020	YES	YES	NO	NO	NO	NO	NO
3	Male	Jun 2020	YES	YES	NO	NO	NO	NO	NO
4	Male	Jun 2020	YES	YES	NO	YES	NO	NO	NO
5	Female	Ju 2020	YES	YES	YES	YES	NO	NO	YES
6	Male	Sep 2020	YES	YES	NO	YES	NO	NO	YES
7	Male	Nov 2020	YES	YES	NO	YES	NO	NO	NO
8	Male	Dec 2020	NO	YES	YES	YES	NO	NO	YES

420

# 422 Table 2. Detection of SARS-CoV-2 RNA in feces and urine of COVID-19 patients

## 423 by RT-qPCR.

Patient code	Sampling date	Specimen	Ct N1	gc/L N1 <sup>*</sup>	Ct N2	gc/L N2 <sup>*</sup>	Cell culture test
1	Jun 2020	Feces	ND ND ND	ND ND	ND ND ND	ND	No
		Urine	ND	ND	43.000	0	
	Jul 2020	Feces	36.664 36.479	$1.13 \times 10^{6}$	ND ND	ND	Yes
		Urine	ND ND	ND	ND ND	ND	
	Jul 2020	Feces	34.304 34.137	$1.60 \times 10^{6}$	38.266 36.346	$1.53 \times 10^{6}$	Yes
		Urine	ND ND	ND	ND ND	ND	
2	Ju  2020	Feces	ND 37.006	$9.43 \times 10^{4}$	41.295 41.281	0	Yes
		Urine	ND ND	ND	42.442 ND	0	
	Ju  2020	Urine	ND ND	ND	ND ND	ND	No
3	Jul 2020	Feces	35.130 33.152	$2.20 \times 10^{6}$	36.122 35.675	$3.43 \times 10^{6}$	Yes
		Urine	ND ND	ND	ND ND	ND	
	Ju  2020	Feces	ND ND	ND	ND ND	ND	No
		Urine	ND ND	ND	43 ND	0	
4	Ju  2020	Feces	31.826 33.183	$6.74 \times 10^{6}$	35.159 35.049	$6.00 \times 10^{6}$	Yes
		Urine	ND ND	ND	ND ND	ND	
	Ju  2020	Feces	ND ND	ND	ND ND	ND	No
		Urine	ND ND	ND	ND ND	ND	
5	Jul 2020	Urine	ND ND	ND	ND ND	ND	No
6	Sep 2020	Feces	38.334 37.578	$5.04 \times 10^{4}$	39.869 ND	$4.49 \times 10^{4}$	Yes
		Urine	ND ND	ND	ND 38.980	$1.78 \times 10^{5}$	
	Sep 2020	Feces	ND 38.967	8.34 × 10 <sup>3</sup>	39.005 39.750	$9.88 \times 10^{4}$	Yes

*	4						
8	Jan 2021	Feces	ND ND	ND	42.730 ND	0	No
7	Nov 2020	Feces	38.599 ND	$1.21 \times 10^{6}$	ND ND	ND	No
		Urine	ND 37.534	$7.46 \times 10^{4}$	ND 39.332	$1.38 \times 10^5$	
	Sep 2020	Feces	ND ND	ND	40.421 40.739	0	Yes
		Urine	37.887 ND	5.60 × 10 <sup>4</sup>	40.458 ND	0	

- 425 \*average gc/L per sample
- 426 ND: non detected

# 428 Table 3. Detection of SARS-CoV-2 RNA in inoculated Vero E6 cultures with

treated feces of COVID-19 patients by RT-qPCR after 0 hpi, 48 hpi and 6 dpi.

430

				0 H	npi			48	hpi				6 dpi	
Patient code	Sampling date	Dilution	Ct N1	gc/L N1 <sup>*</sup>	Ct N2	gc/L N2 <sup>*</sup>	Ct N1	gc/L N1 <sup>*</sup>	Ct N2	gc/L N2 <sup>*</sup>	Ct N1	gc/L N1 <sup>*</sup>	Ct N2	gc/L N2 <sup>*</sup>
1	hul 2020	1/10	ND ND	ND	ND ND	ND	ND ND	ND	ND ND	ND	ND ND	ND	ND ND	ND
1	Ju  2020	Undiluted	ND ND	ND	ND ND	ND	ND ND	ND	ND ND	ND	ND ND	ND	ND ND	ND
	Ju  2020	1/10	ND ND	ND	ND ND	ND	ND ND	ND	ND ND	ND	ND ND	ND	ND ND	ND
	JUI 2020	Undiluted	ND ND	ND	ND ND	ND	ND ND	ND	ND ND	ND	ND ND	ND	ND ND	ND
2	Int 2020	1/10	ND ND	ND	ND ND	ND	38.151 ND	0	ND ND	ND	ND ND	ND	ND ND	ND
2	Ju  2020	Undiluted	ND ND	ND	ND ND	ND	ND ND	ND	40.586 41.534	0	ND ND	ND	ND ND	ND
3	Ju  2020	1/10	ND ND	ND	ND ND	ND	ND ND	ND	41.117 ND	0	ND ND	ND	ND ND	ND
3	JUI 2020	Undiluted	ND ND	ND	ND ND	ND	ND 37.936	0	ND ND	ND	ND ND	ND	ND ND	ND
4		1/10	ND ND	ND	ND ND	ND	ND ND	ND	ND ND	ND	ND ND	ND	ND ND	ND
4	Ju  2020	Undiluted	38.721 39.059	0	ND ND	ND	ND 37.993	0	ND ND	ND	ND ND	ND	N2 ND ND ND ND ND ND ND ND ND ND ND ND ND	ND
6	Sep 2020	1/10	ND ND	ND	ND ND	ND	ND ND	ND	ND 41.001	0	-	-	-	-
б	Sep 2020	Undiluted	ND 37.815	0	ND ND	ND	ND ND	ND	ND ND	ND	-	-	-	-
	Sep 2020	1/10	ND ND	ND	ND ND	ND	ND 38.313	0	ND ND	ND	-	-	-	-
	3ep 2020	Undiluted	ND ND	ND	ND 44.827	0	ND ND	ND	ND 40.613	0	-	-	-	-
	Sep 2020	1/10	ND 37.959	0	41.165 41.22	0	ND ND	ND	ND 40.831	0	-	-	-	-
	3ep 2020	Undiluted	ND ND	ND	ND ND	ND	ND ND	ND	ND ND	ND	-	-	-	-

431 \* average gc/L per sample

432 ND: non detected

- 433
- 434
- 435
- 436

Pinedo 2       29 Jul 2020       30.251 29.993       7.31 × 10 <sup>5</sup> 32.882 32.763       9.91 × 10 <sup>5</sup> Pinedo 2       3 Aug 2020       29.570 31.671       1.77 × 10 <sup>5</sup> 31.381       1.48 × 10         Pinedo 1       3 Aug 2020       32.410 31.671       3.75 × 10 <sup>5</sup> 33.642 33.445       3.93 × 10         Pinedo 1       3 Aug 2020       32.410 32.410       2.05 × 10 <sup>5</sup> 34.783 34.783       1.97 × 10         Pinedo 1       5 Aug 2020       32.781 32.883       1.17 × 10 <sup>5</sup> 35.112 35.018       7.04 × 10         Pinedo 1       17 Aug 2020       31.631 31.631       2.80 × 10 <sup>4</sup> 37.177 40.124       4.81 × 10 <sup>6</sup> Pinedo 1       8 Nov 2020       34.125 34.155       1.30 × 10 <sup>6</sup> 37.833 38.378       5.54 × 10 <sup>6</sup> Pinedo 2       8 Nov 2020       34.122 34.822       1.30 × 10 <sup>6</sup> 37.833 38.378       5.54 × 10 <sup>7</sup> ND: non detected       ND: non detected       1.57 × 10 <sup>8</sup> 1.57 × 10 <sup>8</sup> 1.57 × 10 <sup>8</sup> 9       ND: non detected       1.57 × 10 <sup>8</sup> 1.57 × 10 <sup>8</sup> 1.57 × 10 <sup>8</sup> 9       1.57 × 10 <sup>8</sup> 1.57 × 10 <sup>8</sup> 1.57 × 10 <sup>8</sup> 1.48 × 10 <sup>8</sup> 10       1.58 × 10 <sup>8</sup> 1.58 × 10 <sup>8</sup> 1.58 × 10 <sup>8</sup> <td< th=""><th>- /</th><th></th><th></th><th></th><th>onator by</th><th>··· ٩. •</th><th></th></td<>	- /				onator by	··· ٩. •	
Pinedo 2       29 J0 2020       29 933       7.31 × 10       32.763       9.91 × 10         Pinedo 2       3 Aug 2020       29 570       1.27 × 10 <sup>6</sup> 31.675       1.48 × 10         Pinedo 1       3 Aug 2020       31.507       3.75 × 10 <sup>5</sup> 33.602       3.93 × 10         Pinedo 2       4 Aug 2020       32.410       2.05 × 10 <sup>5</sup> 34.788       1.97 × 10         Pinedo 1       5 Aug 2020       32.781       1.17 × 10 <sup>5</sup> 35.012       7.04 × 10         Pinedo 1       17 Aug 2020       31.631       2.80 × 10 <sup>6</sup> MD       1.43 × 10         Pinedo 1       17 Aug 2020       31.631       1.45 × 10 <sup>5</sup> 37.177       4.81 × 10         Pinedo 1       8 Nov 2020       34.380       1.45 × 10 <sup>5</sup> 37.878       5.54 × 10 <sup>6</sup> 9 inedo 2       8 Nov 2020       34.322       1.30 × 10 <sup>5</sup> 38.378       5.54 × 10 <sup>7</sup> 9 inedo 2       8 Nov 2020       34.822       1.30 × 10 <sup>5</sup> 38.378       5.54 × 10 <sup>7</sup> 9 inedo 1       ND       2.00 × 10 <sup>5</sup> 38.378       5.54 × 10 <sup>7</sup> 38.378       5.54 × 10 <sup>7</sup> 9 inedo 1       17 Aug 200 × 10 <sup>5</sup> 38.378       5.54 × 10 <sup>7</sup> 34.82 <sup>7</sup> 1.30 × 10 <sup>5</sup> <t< th=""><th></th><th>WWTP</th><th>Sampling date</th><th>Ct N1</th><th>gc/L N1<sup>*</sup></th><th>Ct N2</th><th>gc/L N2<sup>*</sup></th></t<>		WWTP	Sampling date	Ct N1	gc/L N1 <sup>*</sup>	Ct N2	gc/L N2 <sup>*</sup>
Pinedo 2 3 Aŭg 2020 29.687 1.27 × 10 31.381 1.48 × 10 Pinedo 1 3 Aug 2020 31.677 3.75 × 10 <sup>5</sup> 33.602 3.93 × 10 <sup>6</sup> Pinedo 2 4 Aug 2020 32.460 2.05 × 10 <sup>6</sup> 34.305 1.97 × 10 Pinedo 1 5 Aug 2020 32.781 1.17 × 10 <sup>3</sup> 35.112 7.04 × 10 Pinedo 1 17 Aug 2020 31.631 2.80 × 10 <sup>6</sup> 32.384 1.43 × 10 Pinedo 1 8 Nov 2020 34.165 1.45 × 10 <sup>5</sup> 40.124 4.81 × 10 Pinedo 2 8 Nov 2020 34.122 1.30 × 10 <sup>6</sup> 37.803 5.54 × 10 8 *average gc/L per sample 9 ND: non detected 0 1 2 3 4 5 6 1		Pinedo 2	29 Ju  2020		7.31 × 10 <sup>5</sup>		$9.91 \times 10^{5}$
Pinedo 1       5 Aug 2020       31.671       5.75 × 10       33.445       5.95 × 10 <sup>3</sup> Pinedo 2       4 Aug 2020       32.410       2.05 × 10 <sup>3</sup> 34.798       1.97 × 10         Pinedo 1       5 Aug 2020       32.880       1.17 × 10 <sup>6</sup> 35.112       7.04 × 10         Pinedo 1       17 Aug 2020       31.631       2.80 × 10 <sup>4</sup> ND       ND       1.43 × 10         Pinedo 1       17 Aug 2020       34.380       1.45 × 10 <sup>5</sup> 37.177       4.81 × 10         Pinedo 1       8 Nov 2020       34.122       1.30 × 10 <sup>4</sup> 38.378       5.54 × 10 <sup>5</sup> 9       ND: non detected       0       34.822       1.30 × 10 <sup>5</sup> 37.803       5.54 × 10 <sup>5</sup> 9       ND: non detected       0       1       10       10       34.822       1.30 × 10 <sup>5</sup> 38.378         9       0       1       2       1.45 × 10 <sup>5</sup> 37.803       5.54 × 10 <sup>5</sup> 11       2       3       3       3       3       3       3         12       3       3       3       3       3       3       3         12       3       3       3       3       3       3		Pinedo 2	3 Aug 2020		1.27 × 10 <sup>6</sup>		$1.48 \times 10^{6}$
Pinedo 2 4 Aug 2020 32.460 2.05 × 10 34.305 1.97 × 10 Pinedo 1 5 Aug 2020 32.781 1.17 × 10 <sup>5</sup> 35.018 7.04 × 10 Pinedo 1 17 Aug 2020 31.833 2.80 × 10 <sup>4</sup> ND Pinedo 1 8 Nov 2020 34.165 1.45 × 10 <sup>5</sup> 37.177 4.81 × 10 Pinedo 2 8 Nov 2020 34.122 1.30 × 10 <sup>5</sup> 37.803 5.54 × 10 8 * average gc/L per sample 9 ND: non detected 0 1 2 3 4 5 6 6 6 7 8 9 0 1 2 3 4 5 6 6 7 8 9 0 1 1 2 3 4 5 6 6 7 8 9 0 1 1 2 3 4 5 6 6 7 8 9 9 1 1 1 1 1 1 1 1 1 1 1 1 1		Pinedo 1	3 Aug 2020		3.75 × 10⁵		$9.91 \times 10^{5}$ $1.48 \times 10^{6}$ $3.93 \times 10^{5}$ $1.97 \times 10^{5}$ $7.04 \times 10^{4}$ $1.43 \times 10^{4}$ $4.81 \times 10^{4}$
Pinedo 1 17 Aug 2020 32.880 1.17 × 10 35.018 7.04 × 10 Pinedo 1 17 Aug 2020 31.633 2.80 × 10 <sup>4</sup> 32.344 1.43 × 10 Pinedo 1 8 Nov 2020 34.152 1.30 × 10 <sup>5</sup> 37.803 5.54 × 10 Pinedo 2 8 Nov 2020 34.122 1.30 × 10 <sup>5</sup> 37.803 38.378 5.54 × 10 * average gc/L per sample ND: non detected ND: non detected ND: non detected 6		Pinedo 2	4 Aug 2020	32.460	$2.05 \times 10^{5}$	34.305	1.97 × 10⁵
Pinedo 1 17 Aug 2020 31.631 2.80 × 10 ND 1.43 × 10 Pinedo 1 8 Nov 2020 34.185 1.45 × 10 <sup>5</sup> 37.177 34.155 1.45 × 10 <sup>5</sup> 37.803 34.822 1.30 × 10 <sup>5</sup> 37.803 38.378 5.54 × 10 8 * average gc/L per sample 9 ND: non detected 0 1 2 3 4 5 6 7 8 9 0 1 2 3 4 5 6 6 6 6 6 6 6 6 7 8 9 0 1 2 3 4 5 6 6 6 6 6 6 6 6 6 6 7 8 9 9 0 1 1 1 1 1 1 1 1 1 1 1 1 1		Pinedo 1	5 Aug 2020	32.880	$1.17 \times 10^{5}$	35.018	7.04 × 10 <sup>4</sup>
Pinedo 1 8 Nov 2020 34.165 1.45 × 10 40.124 4.81 × 10 Pinedo 2 8 Nov 2020 34.822 1.30 × 10 <sup>5</sup> 37.803 5.54 × 10 * average gc/L per sample ND: non detected ND: non detected ND: non detected 6				31.631		ND	1.43 × 10 <sup>4</sup>
Pinedo 2       8 Nov 2020       34.822       1.30×10       38.378       5.54×10         8       'average gc/L per sample         9       ND: non detected         0       1         2       3         3       4         5       6         6       7         8       9         0       1         1       2         3       4         5       6         6       7         6       7         8       9         0       1         2       3         3       4         5       6		Pinedo 1	8 Nov 2020	34.165	1.45 × 10⁵	40.124	$4.81 \times 10^{4}$
<ul> <li>ND: non detected</li> <li>ND: non d</li></ul>					$1.30 \times 10^{5}$		$5.54 \times 10^{4}$
0 1 2 3 4 5 6 7 8 9 0 1 2 3 4 5 6 6 6 6 6 6 6 6 6 6 6 6 6 6 6 6 6 6	88	* average gc/L per samp	ble				
	39	ND: non detected					
2 3 4 5 6 7 8 9 0 1 1 2 3 4 5 6 6	40						
3         4         5         6         7         8         9         0         1         2         3         4         5         6	1						
4         5         6         7         8         9         0         1         2         3         4         5         6	12						
5         6         7         8         9         0         1         2         3         4         5         6	13						
6         7         8         9         0         1         2         3         4         5         6	14						
7         8         9         0         1         2         3         4         5         6	15 16						
8       9         0       1         1       2         3       4         5       6	16 17						
9 0 1 2 3 4 5 6	8						
1 2 3 4 5 6	19						
2 3 4 5 6	50						
3 4 5 6	1						
4 5 6	52						
5 6	3						
6	54						
	55						
7	56						
'	57						

# 437 Table 4. Detection of SARS-CoV-2 RNA in wastewater by RT-qPCR.

# 458

459

## Table 5. Detection of SARS-CoV-2 RNA in inoculated Vero E6 cultures with concentrated wastewater by RT-qPCR after 0 hpi, 48 hpi and 6 dpi.

462

				0	npi			48	hpi			6 c	lpi	
WWTP	Sampling date	Dilution	Ct N1	gc/L N1 <sup>*</sup>	Ct N2	gc/L N2 <sup>*</sup>	Ct N1	gc/L N1 <sup>*</sup>	Ct N2	gc/L N2 <sup>*</sup>	Ct N1	gc/L N1 <sup>*</sup>	Ct N2	gc/ L N2 <sup>*</sup>
Dina da D	29 Jul	1/10	ND ND	ND	42.162 ND	0	ND ND	ND	40.814 ND	0	ND ND	ND	ND ND	ND
Pinedo 2	2020	Undiluted	ND ND	ND	ND ND	ND	ND ND	ND	ND ND	ND	ND ND	ND	ND ND	ND
Din e de D	3 Aug	1/10	ND ND	ND	ND ND	ND	ND ND	ND	ND ND	ND	ND ND	ND	ND ND	ND
Pinedo 2	2020	Undiluted	ND ND	ND	40.609 ND	0	ND ND	ND	ND ND	ND	ND ND	ND	ND ND	ND
Dina da 1	3 Aug	1/10	ND ND	ND	43.000 ND	0	39.885 ND	0	ND ND	ND	ND ND	ND	ND ND	ND
Pinedo 1	2020	Undiluted	ND ND	ND	ND ND	ND	ND ND	ND	41.148 ND	0	ND ND	ND	ND ND	ND
Dinada 2	4 Aug	1/10	ND ND	ND	ND ND	ND	ND ND	ND	ND ND	ND	ND ND	ND	ND ND	ND
Pinedo 2	2020	Undiluted	ND ND	ND	ND ND	ND	ND ND	ND	42.262 ND	0	ND ND	ND	ND ND	ND
Dinada 1	5 Aug	1/10	ND ND	ND	ND ND	ND	ND ND	ND	41.77 41.268	0	ND ND	ND	ND ND	ND
Pinedo 1	2020	Undiluted	ND ND	ND	42.502 ND	0	ND ND	ND	42.508 ND	0	ND ND	ND	ND ND	ND
Dine de 1	17 Aug	1/10	ND 40.858	0	ND ND	ND	38.150 38.137	0	ND ND	ND	ND ND	ND	ND ND	ND
Pinedo 1	2020	Undiluted	39.047 ND	0	ND 41.307	0	ND ND	ND	43.976 ND	0	ND ND	ND	ND ND ND ND ND ND ND ND ND ND ND ND ND N	ND
Dinada 1	8 Nov	1/10	ND ND	ND	ND ND	ND	ND ND	ND	ND ND	ND	ND ND	ND		ND
Pinedo 1	2020	Undiluted	ND ND	ND	ND ND	ND	ND ND	ND	ND ND	ND	ND ND	ND		0
Dinada 2	8 Nov	1/10	ND 37.472	0	ND ND	ND	ND ND	ND	ND ND	ND	ND ND	ND		ND
Pinedo 2	2020	Undiluted	ND ND	ND	ND ND	ND	ND ND	ND	ND ND	ND	38.861 ND	0		0

463 \* average gc/L per sample

464 ND: non detected